Jaypirca (pirtobrutinib) is a novel, non-covalent Bruton's tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. Despite its presence in the market for a little more than 2 months, a survey conducted by ZoomRx with 30 oncologists revealed that less than 40% of them were aware of Jaypirca and only four indicated a high likelihood of using the product.
The open-ended responses provided by the oncologists in the survey suggest that there is cautious optimism about the potential of Jaypirca as a treatment option for relapsed or refractory MCL. Responses such as "novel, cutting edge, promising," "looks promising but I have not yet reviewed the data," and "safety and efficacy are promising" indicate that oncologists recognize the potential of this new therapy. Others highlighted the need for additional therapies for MCL, indicating that Jaypirca may be a welcomed addition to the current treatment options.
Some oncologists noted that Jaypirca is intended for later line treatment and is not a "home run," highlighting the need for up-front first and second-line treatments for MCL. Others expressed interest in the dosing, efficacy, and tolerability of Jaypirca, indicating that these factors may influence their decision to use the product.
Despite the cautious optimism expressed in the open-ended responses, the low awareness and low likelihood of use reported by oncologists in the survey suggest that there may be some hesitancy in adopting this new therapy. However, the fact that Jaypirca is the first FDA-approved non-covalent BTK inhibitor and can re-establish BTK inhibition in MCL patients previously treated with a covalent BTK inhibitor may make it a valuable treatment option for patients who have exhausted other options.
It is important for healthcare providers to remain up-to-date on the latest treatment options for their patients with MCL. As more data on the safety and efficacy of Jaypirca becomes available, oncologists may become more comfortable with using this novel therapy. It will also be important for manufacturers to continue to educate healthcare providers on the benefits and risks of Jaypirca and to ensure that it is appropriately positioned in the treatment landscape for MCL
